Emergency Use Authorization (EUA) Guidebooks and Other CmAb Resources
Welcome! NICA has collaborated with various pharmaceutical manufacturers to develop in-depth guidance about the COVID-19 antibody therapies currently available under Emergency Use Authorization. Links to additional resources on external sites can also be found here.
NICA collaborated with Regeneron to develop this playbook with in-depth information about Casirivimab + Imdevimab.
Important Notice: On June 25, 2021, the FDA is immediately pausing all distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with existing supply of bamlanivimab at a facility for use under EUA 094) on a national basis until further notice.
Eli Lilly Bamlanivimab + Etesevimab Playbook
The CDC has developed the COVID-19 Communication Toolkit: For Migrants, Refugees, and Other Limited-English-Proficient Populations in various languages. Resources are available in Spanish, Simplified Chinese, Korean, Tagalog, Hmoob (Hmong), Af Soomaali (Somali), and Vietnamese.